Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.60 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589086 | 1.00 | IDO1 (0.60) | IDO1IDO2CYP3A4CYP2C9TDO2 | |
| Hydrochloric Acid SCHEMBL29609373 | 0.99 | IDO1 (0.59) | IDO1IDO2CYP3A4CYP2C9TDO2 | |
| Hydrochloric Acid SCHEMBL148937 | 0.99 | IDO1 (0.59) | IDO1IDO2CYP3A4CYP2C9TDO2 | |
| Iodide SCHEMBL145709 | 0.99 | IDO1 (0.59) | IDO1IDO2CYP3A4CYP2C9TDO2 | |
| SCHEMBL10174137 | 0.94 | IDO1 (0.58) | IDO1IDO2CYP3A4CYP2C9TDO2 | |
| Iodide SCHEMBL146073 | 0.93 | IDO1 (0.57) | IDO1IDO2CYP3A4CYP2C9TDO2 | |
| SCHEMBL20090544 | 0.92 | IDO1 (0.58) | IDO1IDO2KCNH2 | |
| SCHEMBL145385 | 0.91 | IDO1 (0.57) | IDO1IDO2KCNH2 | |
| SCHEMBL29099134 | 0.91 | IDO1 (0.57) | IDO1IDO2KCNH2 | |
| SCHEMBL21236561 | 0.90 | IDO1 (0.63) | IDO1IDO2CYP3A4CYP2C9TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911669-B1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | UNIV CHICAGO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3617198-B1 | GUANIDINE DERIVATIVE | LUNAN PHARMACEUTICAL GROUP CORP (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-107304191-B | Indolylamine 2,3-dioxygenase inhibitor and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-107954999-B | Oxadiazole ring-containing compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-109810104-B | Method for synthesizing indoleamine 2, 3-dioxygenase inhibitors | 因赛特控股公司 | 2022-05-03 | — | — | CN | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| CN-109111438-B | Amidine compounds for IDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-04-06 | — | — | US | disclosed |
| EP-2824100-A1 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Corporation (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2315756-B1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
| WO-2010005958-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885IDO2 2/4885CYP3A4 131/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885IDO2 2/4885CYP3A4 131/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885IDO2 2/4885CYP3A4 131/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | IDO1 3/4885IDO2 6/4885CYP3A4 2311/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885IDO2 2/4885CYP3A4 131/4885 |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, IDO1, IL2 | IDO1 2/4885IDO2 5/4885CYP3A4 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.